Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIOUS II
2024-515998-94-00Phase 3Authorised
- Sponsor
- Rigshospitalet
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olanzapine and HiDex in coronary arteriosclerosis and aortic valve disease (AVD) (4 arms), sponsored by Rigshospitalet. Primary endpoint: Days alive and outside hospital within 90 days after surgery. Planned start Oct 2024; status: authorised.
02
Drugs
olanzapineHiDex
03
Conditions
coronary arteriosclerosisaortic valve disease (AVD)
Beyond the preview
Go deeper on 2024-515998-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515998-94-00.